EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes

A Quinlivan, D Neuen, D Hansen, W Stevens, L Ross, N Ferdowsi, S M Proudman, J G Walker, J Sahhar, G-S Ngian, D Apostolopoulos, L V Host und 4 weitere

Arthritis Research & Therapy · 25.06.2024 · 26 (1)

DOI: 10.1186/s13075-024-03355-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Research & Therapy, online erschienen am 25.06.2024. Verfasst von A Quinlivan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, St Vincent's Hospital (Melbourne), 35 Victoria Parade, Fitzroy, Victoria, 3065, Australia. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Lung Diseases, Interstitial, Scleroderma, Systemic, Proton Pump Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Melbourne, Royal Australian College of Physicians, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc).

Methods

SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA) and/or the presence of reflux oesophagitis diagnosed endoscopically. The impact of GORD and its treatment on ILD features (including severity and time to ILD development) and survival was evaluated.

Results

GORD was a common manifestation affecting 1539/1632 (94%) of SSc patients. GORD affected 450/469 (96%) of those with SSc-ILD cohort. In SSc-ILD, there was no relationship between the presence of GORD or its treatment and time to ILD development or ILD severity. However, GORD treatment was associated with improved survival in those with ILD ( p = 0.002). Combination therapy with both a PPI and a H2RA was associated with a greater survival benefit than single agent therapy with PPI alone (HR 0.3 vs 0.5 p < 0.050 respectively).

Conclusion

GORD is a common SSc disease manifestation. While the presence or treatment of GORD does not influence the development or severity of ILD, aggressive GORD treatment, in particular with a combination of PPI and H2RA, is associated with improved survival in those with SSc-ILD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastroesophageal RefluxLung Diseases, InterstitialScleroderma, SystemicProton Pump InhibitorsHistamine H2 AntagonistsHumansFemaleMaleMiddle AgedAgedAdultCohort StudiesTreatment OutcomeAustralia

Stichwörter der Autor:innen

Gastro-oesophageal reflux diseaseInterstitial lung diseaseSystemic sclerosis

Substanzen

Proton Pump InhibitorsHistamine H2 Antagonists

Autor:innen und Institutionen

  • Department of Rheumatology, St Vincent's Hospital (Melbourne), 35 Victoria Parade, Fitzroy, Victoria, 3065, Australia.
  • Department of Medicine, The University of Melbourne at St Vincent's Hospital (Melbourne), 41 Victoria Parade, Fitzroy, Victoria, 3065, Australia.
  • Department of Rheumatology, Liverpool Hospital, Corner of Elizabeth St and Goulburn St, Liverpool, 2170 NSW, Australia.
  • Rheumatology Unit, Royal Adelaide Hospital (Adelaide), Port Rd, Adelaide, South Australia, 5000, Australia.
  • Discipline of Medicine, University of Adelaide (Adelaide), North Terrace, Adelaide, South Australia, 5000, Australia.
  • Rheumatology Unit, Flinders Medical Centre (Adelaide), Flinders Drive, Bedford Park, South Australia, 5042, Australia.

Förderung

  • University of Melbourne
  • Royal Australian College of Physicians
  • National Health and Medical Research Council

Zitieren

APA

Quinlivan, A., Neuen, D., Hansen, D., Stevens, W., Ross, L., Ferdowsi, N., Proudman, S. M., Walker, J. G., Sahhar, J., Ngian, G. S., Apostolopoulos, D., Host, L. V., Major, G., Basnayake, C., Morrisroe, K., & Nikpour, M. (2024). The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03355-0

Vancouver

Quinlivan A, Neuen D, Hansen D, Stevens W, Ross L, Ferdowsi N, et al. The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes. Arthritis Research & Therapy. 2024;26(1). doi:10.1186/s13075-024-03355-0

BibTeX
@article{Quinlivan2024,
  author = {Quinlivan, A and Neuen, D and Hansen, D and Stevens, W and Ross, L and Ferdowsi, N and Proudman, S M and Walker, J G and Sahhar, J and Ngian, G-S and Apostolopoulos, D and Host, L V and Major, G and Basnayake, C and Morrisroe, K and Nikpour, M},
  title = {The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes},
  journal = {Arthritis Research & Therapy},
  year = {2024},
  volume = {26},
  number = {1},
  doi = {10.1186/s13075-024-03355-0}
}
Kostenlos starten →